{
    "nctId": "NCT01402193",
    "briefTitle": "Study of Arimidex and Radiotherapy Sequencing",
    "officialTitle": "A Prospective, Randomized, Bi-center Study to Compare the Outcome of Adjuvant Radiotherapy With Concomitant or Sequential Arimidex in Postmenopausal Women With Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 220,
    "primaryOutcomeMeasure": "Level of TGF-\u03b21",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Provision of informed consent\n* Pathological confirmation of breast cancer\n* ER(+) and/or PR(+).\n* Post-menopausal woman\n* Age\u226470 years old\n* Breast conservative surgery with axillary dissection or staging by either sentinel nodes biopsy or axillary sampling\n* Post-mastectomy patients with T1-T2 and N1-N3, or T3-T4 with any N Negative surgical margins\n* Karnofsky\u226570\n* Laboratory criteria:\n\n  * PLT\u2265100\\*109/L\n  * WBC\u22654000/mm3\n  * HGB\u226510g/dl\n  * ALT and AST\\<2\\*ULN\n* No presence of metastatic disease\n* No other malignant tumour\n\nExclusion Criteria:\n\n* Presence of metastatic disease.\n* T1, T2, N0 with mastectomy\n* Non-infiltrative breast carcinoma underwent mastectomy\n* Other malignant tumor (concurrent or previous).\n* Positive surgical margins.\n* Patients with demonstrated hypersensitivity to Arimidex or any excipient.\n* Patients with severe renal impairment (creatinine clearance less than 20 ml/min).\n* Patients with moderate or severe hepatic disease.\n* Oestrogen-containing therapies should not be co-administered with Arimidex as they would negate its pharmacological action.\n* Not able or willing to sign informed consent\n* Autoimmune diseases including scleroderma, systemic lupus erythematosus and so on",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}